文献速递淋巴瘤

霍奇金淋巴瘤:2025年诊断、风险分层和管理更新

Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management.
PubMed 文献 · Am J Hematol · 2024-09-06

霍奇金淋巴瘤(HL)是一种不常见的B细胞淋巴恶性肿瘤,在美国每年影响8570例新患者,约占所有淋巴瘤的10%。诊断分为经典型HL和结节性淋巴细胞为主型HL,风险分层依据分期、预后模型和PET反应,初始治疗根据组织学、解剖分期和不良预后特征选择,复发难治患者以HDCT联合ASCT为标准,失败后可考虑brentuximab vedotin、PD-1阻断、非清髓性异基因移植或临床试验。

要点

  • HL分为经典型和结节性淋巴细胞为主型,经典型有4种亚型。
  • 准确分期和预后模型(包括PET反应)用于优化治疗。
  • 复发难治患者标准为HDCT+ASCT,失败后有多种选择。

核心结论

  • HL的诊断、风险分层和治疗需根据组织学、分期、预后特征和PET反应个体化选择,新药已纳入一线治疗,复发难治患者有标准及后续选择。

研究设计与样本

  • 综述,基于美国每年8570例新发HL患者的数据,总结诊断、风险分层和管理更新。

主要发现

  • HL在美国每年影响8570例新患者,约占所有淋巴瘤的10%。
  • HL分为经典型HL和结节性淋巴细胞为主型HL,经典型包括结节硬化型、混合细胞型、淋巴细胞消减型和淋巴细胞丰富型。
  • 早期患者通常接受短程联合化疗后受累野放疗,晚期患者接受较长程化疗常不放疗。
  • brentuximab vedotin和抗PD-1抗体已标准纳入一线治疗。
  • 复发难治患者标准为HDCT+ASCT,失败后可考虑brentuximab vedotin、PD-1阻断、非清髓性异基因移植或临床试验。

关键数值与推荐

  • 准确评估分期对选择合适治疗至关重要。
  • 预后模型识别低危或高危复发患者,PET扫描确定治疗反应,用于优化治疗。
  • 初始治疗基于组织学、解剖分期和不良预后特征。

临床怎么用

  • 早期HL采用短程联合化疗后受累野放疗的联合模式治疗。
  • 晚期HL接受较长程化疗,通常不放疗。
  • 一线治疗标准纳入brentuximab vedotin和抗PD-1抗体。
  • 复发难治患者接受HDCT+ASCT作为标准治疗。
  • HDCT+ASCT失败后考虑brentuximab vedotin、PD-1阻断、非清髓性异基因移植或临床试验。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DISEASE OVERVIEW: Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8570 new patients annually and representing ~10% of all lymphomas in the United States. DIAGNOSIS: HL is composed of two distinct disease entities: classical HL and nodular lymphocyte predominant HL (also called nodular lymphocyte predominant B-cell lymphoma). Nodular sclerosis, mixed cellularity, lymphocyte depletion, and lymphocyte-rich HL are subgroups of classical HL. RISK STRATIFICATION: An accurate assessment of the stage of disease in patients with HL is critical for the selection of the appropriate therapy. Prognostic models that identify patients at low or high risk for recurrence, as well as the response to therapy as determined by positron emission tomography (PET) scan, are used to optimize therapy. RISK-ADAPTED THERAPY: Initial therapy for HL patients is based on the histology of the disease, the anatomical stage and the presence of poor prognostic features. Patients with early-stage disease are typically treated with combined modality strategies utilizing abbreviated courses of combination chemotherapy followed by involved-field radiation therapy, whereas those with advanced stage disease receive a longer course of chemotherapy often without radiation therapy. However, newer agents including brentuximab vedotin and anti-PD-1 antibodies are now standardly incorporated into frontline therapy. MANAGEMENT OF RELAPSED/REFRACTORY DISEASE: High-dose chemotherapy (HDCT) followed by an autologous stem cell transplant (ASCT) is the standard of care for most patients who relapse following initial therapy. For patients who fail HDCT with ASCT, brentuximab vedotin, PD-1 blockade, non-myeloablative allogeneic transplant or participation in a clinical trial should be considered.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Ansell SM. Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024. PMID: 39239794. doi:10.1002/ajh.27470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。